Work

Optimizing Autologous Stem Cell Transplant for High-Risk Patients with Plasma Cell Dyscrasias

Year: 2018

Type: article

Abstract: Early autologous hematopoietic stem cell transplantation (ASCT) is recommended for transplant eligible pts (pts) with newly diagnosed multiple myeloma (MM) as well as AL Amyloidosis (AA). There is an unmet need for measures to minimize non-hematological toxicities without compromising melphalan (MEL) anti-tumor efficacy; this could lead to expansion of transplant eligibility to older pts as wells pts with high-risk cardiac AA. Here, we report outcomes of an integrated ASCT program for high-risk MM and AA pts.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2017.12.081